Stockreport

New Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential for Neoantigen-Directed Immunotherapies

Advaxis, Inc.  (ADXS) 
Last advaxis, inc. earnings: 9/9 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.advaxis.com
PDF CD8+ T Cell Reactivity Against 90% of Personalized Neoantigen Targets Confirmed in First of Two PatientsProof-of-Mechanism for Off-the-Shelf ADXS-HOT Program with CD8+ T [Read more]